Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below

      DUODOPA (levodopa/carbidopa intestinal gel)

      triple all 2
      triple all 4

      DUODOPA
      (levodopa/carbidopa intestinal gel)

      triple all 2
      triple all 4

      PRODUODOPA (foslevodopa/foscarbidopa solution for infusion)

      triple all 2
      triple all 4

      PRODUODOPA
      (foslevodopa/foscarbidopa solution for infusion)

      triple all 2
      triple all 4

      Neurology

      A look at Complex/Advanced Parkinson's disease
      DUODOPA® (levodopa/carbidopa intestinal gel)
      PRODUODOPA® (foslevodopa/foscarbidopa solution for infusion)

      Levodopa may activate malignant melanoma, so PRODUODOPA and DUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.1,2

      DUODOPA (levodopa/carbidopa intestinal gel) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1

      PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.2

      Some patients may not be suitable for DUODOPA or PRODUODOPA. You are strongly advised to read the Prescribing Information (PI) and Summary of Product Characteristics (SmPC), accessible via the links above, to evaluate patient suitability for DUODOPA and PRODUODOPA.

      Please refer to the DUODOPA or PRODUODOPA Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      References

      1. DUODOPA (levodopa/carbidopa intestinal gel) SmPC.
      2. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) SmPC.
      DUODOPA PRESCRIBING INFORMATION
      PRODUODOPA PRESCRIBING INFORMATION

      By clicking the links above you will leave the AbbVie Pro website and be taken to the eMC PI portal website

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      UK-ABBV-240304. Date of preparation: December 2024

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.